Check out this research letter in @jamahealthforum.com from DGIM's Matthew Klebanoff, Jalpa Doshi, and Pengxiang Li et al. on how the Inflation Reduction Act is reshaping Medicare Part D formulary coverage of MS disease-modifying therapies.
How did #Medicare Part D coverage of multiple sclerosis therapies change after the #InflationReductionAct? LDI Fellows found that after 2025, Part D plans increasingly covered generic disease-modifying therapies when available, while brand-name coverage declined. Read more: https://bit.ly/4fI7hlw